Kenta Biotech AG
  • Home
  • Shop
  • Events
  • Courses
  • Services
  • Pricing
  • Company
    • Blog
    • Success Stories
    • About Us
  • Appointment
  • Contact us
  • 0
  • +1 (718) 513-2983
  • Sign in
  • Contact Us
Kenta Biotech AG
  • 0
    • Home
    • Shop
    • Events
    • Courses
    • Services
    • Pricing
    • Company
      • Blog
      • Success Stories
      • About Us
    • Appointment
    • Contact us
  • +1 (718) 513-2983
  • Sign in
  • Contact Us
  1. Products
  2. RNA research
Public Pricelist
Public Pricelist
Sort By: Featured
Featured Newest Arrivals Name (A-Z) Price - Low to High Price - High to Low

RNA research

[0708-MOB-0296MC] Rabbit Anti-T7 RNA Polymerase Antibody - 1mG.
Rabbit Anti-T7 RNA Polymerase Antibody - 1mG.
4,837.00 € 4837.0 EUR
[1042-14606ES72-250U] RNase R (20 U/μL), 250U
RNase R (20 U/μL), 250U
181.00 € 181.0 EUR
[1042-14606ES72-2500U] RNase R (20 U/μL), 2500U
RNase R (20 U/μL), 2500U
997.00 € 997.0 EUR
[0171-E049] RNase R	500 U (50 μl)
RNase R 500 U (50 μl)
235.00 € 235.0 EUR
[0813-DE111-01] RNase A (100 mG./ml) - 500 μL
RNase A (100 mG./ml) - 500 μL
58.00 € 58.0 EUR
[0171-G073] RNAifectin Transfection Reagent - 1.0 ml (100-500 transfections)
RNAifectin Transfection Reagent - 1.0 ml (100-500 transfections)
346.00 € 346.0 EUR
[0317-NOR.48700] RNA/DNA Purification Test - 50 preps
RNA/DNA Purification Test - 50 preps
648.15 € 648.15 EUR
[0253-CS-502] RNA-Bee/RNA STAT-60 (500 ml)
RNA-Bee/RNA STAT-60 (500 ml)
1,122.50 € 1122.5 EUR
[0253-CS-110-100ml] RNA-Bee/RNA STAT 60 CS-110 -100mL
RNA-Bee/RNA STAT 60 CS-110 -100mL
418.00 € 418.0 EUR
[0253-CS-111] RNA-Bee / RNA Stat 60 - 200 ml
RNA-Bee / RNA Stat 60 - 200 ml
564.00 € 564.0 EUR
[0036- RNA/ DV200] RNA extraction and DV200 per sample
RNA extraction and DV200 per sample
425.00 € 425.0 EUR
[0253-CS-112] RNA Stat-60TM - 50 ml
RNA Stat-60TM - 50 ml
353.00 € 353.0 EUR
[0253-CS–502] RNA STAT-60 (500 ml)
RNA STAT-60 (500 ml)
1,123.00 € 1123.0 EUR
[0966-BIOPEXT-0613.100] RNA Extraction Viral Test Biopremier 100 preps
RNA Extraction Viral Test Biopremier 100 preps
495.00 € 495.0 EUR
[0036-R1234148-10] RNA - Adult Normal Tissue: Peripheral Blood Leukocyte
RNA - Adult Normal Tissue: Peripheral Blood Leukocyte
544.00 € 544.0 EUR
[0337-P0050-30] ProCipitate (Substitute to Phenol/Chloroform for Hemoglobin & Protein Removal, Isolation of DNA/RNA) -	30 mL
ProCipitate (Substitute to Phenol/Chloroform for Hemoglobin & Protein Removal, Isolation of DNA/RNA) - 30 mL
703.00 € 703.0 EUR
[0076-PVR100] Plant Virus RNA Test - Individual Packed Columns 100 rxs
Plant Virus RNA Test - Individual Packed Columns 100 rxs
454.00 € 454.0 EUR
[0171-38224111] PVT1 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human)
PVT1 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human)
537.88 € 537.88 EUR
[0171-38224121] PVT1 CRISPRa sgRNA lentivector (set of three targets)(Human)
PVT1 CRISPRa sgRNA lentivector (set of three targets)(Human)
512.38 € 512.38 EUR
[0820-PVTB00948-3a] PPLK/GFP+PURO-ATG4B SHRNA-1 PLASMID
PPLK/GFP+PURO-ATG4B SHRNA-1 PLASMID
495.00 € 495.0 EUR
  • 4
  • 5
  • 6
  • 7
  • 8

Clear Filters



Respiratory syncytial virus (RSV) infections are the most common cause of hospitalization in early childhood, accounting for 57 000 to 120 000 hospitalizations each year in the United States. RSV is causing annual epidemics of bronchiolitis and pneumonia worldwide. In most cases the infection with RSV heals without sequelae, yet RSV infection can cause lung function deterioration and in some circumstances, years of recurrent wheezing or asthma may ensue. Overall RSV accounts for an estimated2% of the hospitalization rate among infants less than 1 year of age. This rate increases 4–5-fold among high-risk patients such as premature infants and those with chronic lung disease or complicated congenital heart disease.


Currently there is only one possibility to prevent infections of at-risk patients with RSV, namely immuno-prophylaxis with palivizumab/Synagis, marketed by MedImmune. However, the response to palivizumab is variable among individuals, and sometimes palivizumab fails to prevent RSV infections effectively.


Due to the lack of better antibodies, lack of effective anti-viral treatment and lack of an effective preventive vaccine for RSV, there is a substantial medical need for more efficacious prophylactic immunizations, e.g. by antibody.


Kenta Biotech had developed a fully human monoclonal antibody (KBRV201) derived from B-cells of a human donor. KBRV201 is of the human IgG1 isotype with specificity and very high affinity for the F-protein of human respiratory syncytial virus (hRSV). KBRV201 has been tested for recognition and neutralization of hRSV strains -A, -B and –Long, and KBRV201 could neutralize in vitro all strains tested with higher efficacy than other anti-F-protein mAb.




KBRV201 successfully recognizes 22 clinical isolates from children infected with RSV, including one isolate with a mutated F-protein. Overall KBRV201 has demonstrated superiority in every experiment performed, and KBRV201 is currently undergoing extensive testing in animal models.

14009 NW Harbor Ln, Portland, OR 97229, USA.


Follow us
Copyright © 2025 Kenta Biotech AG
English (UK) English (US)